Micropharm Limited

Health Protection Agency

The Secretary of State for Health

Oxford University Innovation Limited

Secretary of State for Health and Social Care

John Landon

Clifford Charles Shone

April Roberts

Michael Maynard-Smith

David Stuart

Miles Carroll

Stuart Dowall

Roger Hewson

Thomas Bowden

Ruth Elizabeth Coxon

Helen Ahern

Ian Cameron

Antra Zeltina

The present invention is directed to an antibody composition for oral administration comprising intact blood-derived polyclonal antibodies that bind to a human tumour necrosis factor &#x3b1; (TNF&#x3b1;), and means for protecting the antibodies during gastrointestinal transit, as well as methods for manufacturing, kits, and therapeutic uses of the same.

Ovine derived human TNF&#x3b1; polyclonal antibody composition for oral administration

The present invention provides antibodies, for use in the treatment, suppression prevention of Filovirus disease, particularly Ebola virus disease. Also provided immunogens for use in eliciting such antibodies.

Filovirus therapy

The present invention relates to recombinantantigens based on a fusion protein that consists of or comprises a first amino acid sequence and a second amino acid sequence, wherein: a) the first amino acid sequence is provided by an amino acid sequence that has at least 80% sequence identity with an amino acid sequence consisting of residues 500-1850 of aToxin A sequence or residues 1500-1851 of aToxin B sequence; and b) the second amino acid sequence is provided by an amino acid sequence that has at least 80% sequence identity with an amino acid sequence consisting of a long repeat unit located within amino acid residues 1851-2710 of aToxin A sequence or within amino acid residues 1852-2366 of aToxin B sequence; though with the proviso that the fusion protein is not a polypeptide comprising amino acid residues 543-2710 of aToxin A and with the proviso that the fusion protein is not a polypeptide comprising amino acid residues 543-2366 of aToxin B. Also provided is the use of said antigens for the prevention/treatment/suppression ofinfection (CDI), together with methods for generating said antigens, methods for generating antibodies that bind to said antigens, and the use of said antibodies for the prevention/treatment/suppression of CDI.

antigens

The present invention provides an antibody composition comprising ovine antibodies, for use in the prevention or treatment ofinfection wherein the antibodies bind to atoxin, and wherein said prevention or treatment is by oral delivery of the antibody composition. Also provided is a pharmaceutical composition of ovine antibodies for oral delivery, which further comprises one or more means for protecting the antibodies from trypsin and/or chymotrypsin and/or stomach acid.

[object Object]

The present invention provides an antibody composition comprising ovine antibodies, for use in the prevention or treatment ofinfection wherein the antibodies bind to atoxin.

Growing community of inventors

Newcastle Emlyn, United Kingdom

John Landon